(HealthDay): for patients with small cell non-cell lung cancer (NSCLC), advanced immune control point inhibitor, pretreatment by chemotherapy, immune control point inhibitor (NS), ipilimumab added at nivolumab does not improve results compared to nivolumab alone, according to a study published online July 15 Oncology JAMA.
Scott N. Gettinger, MD, of the Yale Cancer Center in New Haven, Connecticut, and colleagues enrolled 252 patients with advanced, pretreated, untreated SqNSCLC, and a Zubrod score of 0 (asymptomatic) to 1 (symptomatic but completely outpatient) with disease progression after standard platinum-based chemotherapy in a phase 3 open-label trial. Participants were randomly assigned to nivolumab / ipilimumab or nivolumab alone (125 and 127, respectively).
In a planned interim analysis, the study closed as useless. The researchers did not observe any significant difference between the groups in overall survival (risk ratio, 0.87; 95% confidence interval, 0.66 to 1.16; P = 0.34). Mean survival was 10 and 11 months in the nivolumab / ipilimumab and nivolumab groups, respectively. The researcher has been evaluated progression-free survival (IA-PFS) the risk ratio was 0.80 (95% confidence interval, 0.61 to 1.03; P = 0.09); the mean AI-PFS was 3.8 and 2.9 months, respectively, for nivolumab / ipilimumab and nivolumab. Adverse events related to grade 3 or higher treatment occurred in 39.5 and 33.3 percent of those receiving nivolumab / ipilimumab and nivolumab, respectively.
“Currently, there is no immunotherapy option for patients experiencing disease progression in scheduled therapy with axis 1 death inhibitors,” the authors write.
Several authors revealed financial links with biopharmaceutical companies, including Bristol Myers Squibb, the maker of ipilimumab.
Summary / Full text
Copyright © 2021 HealthDay. All rights reserved.
Citation: Adding ipilimumab to nivolumab is no better in pretreated small squamous cell lung cancer (2021, July 16) retrieved July 17, 2021 from https://medicalxpress.com/news/2021-07-adding- ipilimumab-nivolumab-pretreated-squamous .html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.